We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: March 28 at 4:59:51 PM GMT-3 ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

The Fund seeks to provide long-term capital appreciation. The Fund invests primarily in a broad range of equity securities without limitation to market capitalization. The Fund seeks to invest in ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Analysts' ratings for Gilead Sciences (NASDAQ:GILD) over the last quarter vary from bullish to bearish, as provided by 15 analysts. The following table encapsulates their recent ratings ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since he took the reins in 2019. O’Day received a compensation package of ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...